Vineet Kwatra

430 total citations
8 papers, 57 citations indexed

About

Vineet Kwatra is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Vineet Kwatra has authored 8 papers receiving a total of 57 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 3 papers in Pulmonary and Respiratory Medicine and 2 papers in Molecular Biology. Recurrent topics in Vineet Kwatra's work include Cancer Immunotherapy and Biomarkers (4 papers), Cancer Research and Treatments (2 papers) and CAR-T cell therapy research (2 papers). Vineet Kwatra is often cited by papers focused on Cancer Immunotherapy and Biomarkers (4 papers), Cancer Research and Treatments (2 papers) and CAR-T cell therapy research (2 papers). Vineet Kwatra collaborates with scholars based in Australia, United States and South Korea. Vineet Kwatra's co-authors include Narayan Karanth, Andrew Hill, Ke He, Alexander Guminski, Jun Zhao, Jing Fang, Jing Wang, Siwen Hu‐Lieskovan, Omid Hamid and Zhi Wang and has published in prestigious journals such as Journal of Clinical Oncology, Experimental Biology and Medicine and Journal of Thoracic Oncology.

In The Last Decade

Vineet Kwatra

8 papers receiving 56 citations

Peers

Vineet Kwatra

ONCOL

TRANS

IMMUN

EPIDE

PRM

Eline de Boer Norway

Akshay Krishnamurthy Netherlands

Giovanni Pisapia Italy

Andressa Dias Costa United States

Abigail Gault United Kingdom

Judith Sirokay Germany

Ankit Rao United Kingdom

Nira A. Krasnow United States

Jean Bustamante Alvarez United States

Coriolan Lebreton France

Eline de Boer Norway

Vineet Kwatra

34 ×0.7

ONCOL

2 ×0.1

TRANS

30 ×2.5

IMMUN

9 ×1.3

EPIDE

5 ×0.8

PRM

Citations per year, relative to Vineet Kwatra Vineet Kwatra (= 1×) peers Eline de Boer

Countries citing papers authored by Vineet Kwatra

Since Specialization

Citations

This map shows the geographic impact of Vineet Kwatra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vineet Kwatra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vineet Kwatra more than expected).

Fields of papers citing papers by Vineet Kwatra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vineet Kwatra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vineet Kwatra. The network helps show where Vineet Kwatra may publish in the future.

Co-authorship network of co-authors of Vineet Kwatra

This figure shows the co-authorship network connecting the top 25 collaborators of Vineet Kwatra. A scholar is included among the top collaborators of Vineet Kwatra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vineet Kwatra. Vineet Kwatra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Bui, Nam Q., Vineet Kwatra, Christopher W. Ryan, et al.. (2024). Phase 2a results of SQ3370, a doxorubicin-based click chemistry therapeutic in patients with advanced STS: Planned interim analysis.. Journal of Clinical Oncology. 42(16_suppl). 11555–11555. 2 indexed citations

2.

Starodub, Alexander, Sung‐Bae Kim, Diwakar Davar, et al.. (2024). TransCon IL-2 β/γ alone or in combination with pembrolizumab, standard of care chemotherapy or TransCon TLR7/8 agonist in advanced/metastatic solid tumors: Updated results of the phase 1/2 IL Believe study.. Journal of Clinical Oncology. 42(16_suppl). 2601–2601. 1 indexed citations

3.

Zareian, Nahid, Oleg Eremin, Hardev Pandha, et al.. (2024). A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor mechanisms. Experimental Biology and Medicine. 249. 10021–10021. 2 indexed citations

4.

Thomas, Jacob, J. Eva Selfridge, Costantine Albany, et al.. (2024). Phase 1 study of BA3071, an anti–CTLA-4 conditionally active biologic, in combination with nivolumab in advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2602–2602. 1 indexed citations

5.

Zhou, Qunfang, Bo Gao, Jing Hu, et al.. (2024). OA06.03 SAFFRON-301: Tislelizumab Plus Sitravatinib in Advanced/Metastatic NSCLC Progressing on/after Chemotherapy and Anti-PD-(L)1. Journal of Thoracic Oncology. 19(10). S19–S20. 3 indexed citations

6.

Chawla, Sant P., Maša Alečković, Vivek A. Bhadri, et al.. (2022). Interim phase 1 results for SQ3370 in advanced solid tumors.. Journal of Clinical Oncology. 40(16_suppl). 3085–3085. 2 indexed citations

7.

Kwatra, Vineet, et al.. (2021). Bilateral facial nerve palsy associated with amphiphysin antibody in metastatic breast cancer: a case report. Journal of Medical Case Reports. 15(1). 158–158. 3 indexed citations

8.

Kwatra, Vineet, et al.. (2017). Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report. Journal of Medical Case Reports. 11(1). 73–73. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact